Gilead Sciences posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst ...

Gilead Sciences (NASDAQ: GILD) Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET 2 Big Tech companies had a major flaw in ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it had net income ...

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...

Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Reports Q4 revenue $7.6B, consensus $7.15B. “Gilead (GILD) delivered another exceptionally strong full year and fourth quarter, with growth in ...